Trial reportEuropean journal of nuclear medicine and molecular imaging2005
Biodistribution of radiolabelled human dendritic cells injected by various routes.
Trial report in European journal of nuclear medicine and molecular imaging, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 62 citations in OpenAlex.
- Neoantigen dendritic cell vaccination combined with conventional chemotherapy for a patient with advanced transverse colon cancer.Journal of surgical case reports · 2026Article
- Cancer mRNA vaccines: clinical advances and future opportunities.Nature reviews. Clinical oncology · 2024Review
- Dendritic cell vaccine of gliomas: challenges from bench to bed.Frontiers in immunology · 2023Review
- Direct Cell Radiolabeling forChemical reviews · 2022Review
- Review
- A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells.The Journal of clinical investigation · 2021Article
- Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies.International journal of molecular sciences · 2021Review
- Prostaglandin ECancer immunology, immunotherapy : CII · 2020Article
- Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.International journal of cancer · 2019Article
- Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?International journal of molecular sciences · 2019Review
- The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- The development of dendritic cell vaccine-based immunotherapies for glioblastoma.Seminars in immunopathology · 2017Review
- Shuttling Tolerogenic Dendritic Cells across the Blood-Brain BarrierFrontiers in immunology · 2017Article
- Image-guided dendritic cell-based vaccine immunotherapy in murine carcinoma models.American journal of translational research · 2017Review
- Dendritic cells in cancer immunotherapy clinical trials: are we making progress?Frontiers in immunology · 2013Review
- A comprehensive analysis of transfection-assisted delivery of iron oxide nanoparticles to dendritic cells.Nanomedicine : nanotechnology, biology, and medicine · 2013Article
- In vivo imaging of lymph node migration of MNP- and (111)In-labeled dendritic cells in a transgenic mouse model of breast cancer (MMTV-Ras).Molecular imaging and biology · 2012Article
- Regulation of immune responses by prostaglandin E2.Journal of immunology (Baltimore, Md. : 1950) · 2012Review
- In vivo imaging of immune cell trafficking in cancer.European journal of nuclear medicine and molecular imaging · 2011Review
- Overview of cellular immunotherapy for patients with glioblastoma.Clinical & developmental immunology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to investigate the biodistribution of mature dendritic cells (DCs) injected by various routes, during a cell therapy protocol.
methodsIn the context of a vaccine therapy protocol for melanoma, DCs matured with Ribomunyl and interferon-gamma were labelled with( 111)In-oxine and injected into eight patients along various routes: afferent lymphatic vessel (IL) (4 times), lymph node (IN) (5 times) and intradermally (ID) (6 times).
resultsScintigraphic investigations showed that the IL route allowed localisation of 80% of injected radioactivity in eight to ten nodes. In three cases of IN injection, the entire radioactivity stagnated in the injected nodes, while in two cases, migration to adjacent nodes was observed. This migration was detected rapidly after injection, as with IL injections, suggesting that passive transport occurred along the physiological lymphatic pathways. In two of the six ID injections, 1-2% of injected radioactivity reached a proximal lymph node. Migration was detectable in the first hour, but increased considerably after 24 h, suggesting an active migration mechanism. In both of the aforementioned cases, DCs were strongly CCR7-positive, but this feature was not a sufficient condition for effective migration. In comparison with DCs matured with TNF-alpha, IL-1beta, IL-6 and PGE2, our DCs showed a weaker in vitro migratory response to CCL21, despite comparable CCR7 expression, and higher allostimulatory and TH1 polarisation capacities.
conclusionThe IL route allowed reproducible administration of specified numbers of DCs. The IN route sometimes yielded fairly similar results, but not reproducibly. Lastly, we showed that DCs matured without PGE2 that have in vitro TH1 polarisation capacities can migrate to lymph nodes after ID injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.